目的探讨急性冠状动脉综合征患者内皮组织纤溶酶原激活剂储备功能的变化规律。
Objective To study the changes of the endothelial tissue plasminogen activator reserve capacity in patients with acute coronary syndromes.
公众应当认识到，只有食品和药物管理局核准的中风治疗药物(组织型纤溶酶原激活剂)必须在症状出现的3小时内给予。
The public should be aware that the only Food and Drug Administration-approved stroke treatment medication must be administered within 3 hours of symptom onset.
目的观察应用重组组织型纤溶酶原激活剂溶栓治疗急性心肌梗死的效果。
Objective to observe the effect of recombinant tissue plasminogen activator in the treatment of acute myocardial infarction.
本文用尿激酶(UK)和人体组织型纤溶酶原激活剂(t - PA)进行了兔髂股动脉血栓实验性溶解的对照研究。
The thrombolytic effect was compared between urokinase (UK) and human tissue plasminogen activator (t-PA) in rabbits with experimental iliofemoral artery thrombus.
据报道，纳豆激酶有和胞浆素一样的可直接分解纤维蛋白的生物特性，或者增强尿激酶原和t—PA(人组织型纤溶酶原激活剂)的活性。
According to reports, Nattokinase has plasmin-like bio-characteristic that lyses fibrin directly, or increases activity of pro-urokinase and t-PA (Tissue Plasminogen Activator).
据报道，纳豆激酶有和胞浆素一样的可直接分解纤维蛋白的生物特性，或者增强尿激酶原和t—PA(人组织型纤溶酶原激活剂)的活性。
According to reports, Nattokinase has plasmin-like bio-characteristic that lyses fibrin directly, or increases activity of pro-urokinase and t-PA (Tissue Plasminogen Activator).
应用推荐